Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43926616" target="_blank" >RIV/00064173:_____/24:43926616 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68407700:21460/24:00375764 RIV/00216208:11120/24:43926616 RIV/00098892:_____/24:10158630 RIV/00023001:_____/24:00084687 RIV/60076658:12110/24:43908584

Výsledek na webu

<a href="https://doi.org/10.1093/europace/euae040" target="_blank" >https://doi.org/10.1093/europace/euae040</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/europace/euae040" target="_blank" >10.1093/europace/euae040</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial

Popis výsledku v původním jazyce

BACKGROUND AND AIMS: Data on the hybrid atrial fibrillation (AF) treatment are lacking in patients with structural heart disease undergoing concomitant CryoMaze procedures. The aim was to assess whether the timely pre-emptive catheter ablation would achieve higher freedom from AF or atrial tachycardia (AT) and be associated with better clinical outcomes than surgical ablation alone. METHODS: The trial investigated patients with non-paroxysmal AF undergoing coronary artery bypass grafting and/or valve repair/replacement with mandatory concomitant CryoMaze procedure who were randomly assigned to undergo either radiofrequency catheter ablation (Hybrid Group) or no further treatment (Surgery Group). The primary efficacy endpoint was the first recurrence of AF/AT without class I or III antiarrhythmic drugs as assessed by implantable cardiac monitors. The primary clinical endpoint was a composite of hospitalisation for arrhythmia recurrence, worsening of heart failure, cardioembolic event, or major bleeding. RESULTS: We analysed 113 and 116 patients in the Hybrid and Surgery Groups, respectively, with a median follow-up of 715 (IQR: 528-1072) days. The primary efficacy endpoint was significantly reduced in the Hybrid Group (41.1% vs 67.4%, hazard ratio (HR)=0.38, 95% confidence interval (CI): 0.26-0.57, P&lt;0.001) as well as the primary clinical endpoint (19.9% vs 40.1%, HR=0.51, 95% CI: 0.29-0.86, P=0.012). The trial groups did not differ in all-cause mortality (10.6% vs 8.6%, HR=1.17, 95%CI: 0.51-2.71, P=0.71). The major complications of catheter ablation were infrequent (1.9%). CONCLUSIONS: Pre-emptively performed catheter ablation after the CryoMaze procedure was safe and associated with higher freedom from AF/AT and improved clinical outcomes.

Název v anglickém jazyce

Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial

Popis výsledku anglicky

BACKGROUND AND AIMS: Data on the hybrid atrial fibrillation (AF) treatment are lacking in patients with structural heart disease undergoing concomitant CryoMaze procedures. The aim was to assess whether the timely pre-emptive catheter ablation would achieve higher freedom from AF or atrial tachycardia (AT) and be associated with better clinical outcomes than surgical ablation alone. METHODS: The trial investigated patients with non-paroxysmal AF undergoing coronary artery bypass grafting and/or valve repair/replacement with mandatory concomitant CryoMaze procedure who were randomly assigned to undergo either radiofrequency catheter ablation (Hybrid Group) or no further treatment (Surgery Group). The primary efficacy endpoint was the first recurrence of AF/AT without class I or III antiarrhythmic drugs as assessed by implantable cardiac monitors. The primary clinical endpoint was a composite of hospitalisation for arrhythmia recurrence, worsening of heart failure, cardioembolic event, or major bleeding. RESULTS: We analysed 113 and 116 patients in the Hybrid and Surgery Groups, respectively, with a median follow-up of 715 (IQR: 528-1072) days. The primary efficacy endpoint was significantly reduced in the Hybrid Group (41.1% vs 67.4%, hazard ratio (HR)=0.38, 95% confidence interval (CI): 0.26-0.57, P&lt;0.001) as well as the primary clinical endpoint (19.9% vs 40.1%, HR=0.51, 95% CI: 0.29-0.86, P=0.012). The trial groups did not differ in all-cause mortality (10.6% vs 8.6%, HR=1.17, 95%CI: 0.51-2.71, P=0.71). The major complications of catheter ablation were infrequent (1.9%). CONCLUSIONS: Pre-emptively performed catheter ablation after the CryoMaze procedure was safe and associated with higher freedom from AF/AT and improved clinical outcomes.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/NV19-02-00046" target="_blank" >NV19-02-00046: Sekvenční hybridní ablace versus samostatný chirurgický CryoMAZE v léčbě fibrilace síní (studie SurHyb): multicentrická randomizovaná kontrolovaná studie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Europace

ISSN

1099-5129

e-ISSN

1532-2092

Svazek periodika

26

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

"euae040"

Kód UT WoS článku

001163513100002

EID výsledku v databázi Scopus

2-s2.0-85185277401